PARANEOPlastic cerebellar degeneration associated with anti-ITPR1 antibodies

In recent years, the spectrum of anti-Purkinje cell autoimmunity has widened to include novel clinicoinmunologic entities, a number of which have been associated with antibodies targeting intracellular antigens (protein kinase C gamma (PKCγ), carbonic anhydrase–related protein (CARP VIII), Ca2+/Rho GTPase activating protein 26 (ARHGAP26), inositol 1,4,5-trisphosphate receptor 1 (ITPR1), and HOMER3).1-3 Anti-ITPR1 belong to this group of newly discovered anticerebellar autoantibodies,4 but little is known regarding the exact clinical and paraclinical phenotypes associated with these antibodies and their potential association with cancer.

Here, we report a young woman, carrier of a detrimental germline mutation in the BRCA1 gene, who at the age of 28 years developed autoimmune cerebellar ataxia associated with anti-ITPR1 antibodies with no associated malignancy, but 11 years later was diagnosed with a breast cancer with ITPR1 expression detected on the tumor.

Case report. A 31-year-old Martinican woman was investigated in view of a 3-year history of subtly progressive ataxia. Neurologic examination revealed a static-kinetic cerebellar syndrome characterized by moderate gait ataxia and mild dysarthria. In addition, she was obese and had arterial hypertension. There was no history of excess alcohol intake. She had no family history of neurologic disease but a history of breast cancer in her maternal side. Brain MRI revealed pontocerebellar atrophy with hot cross bun sign, without any other supratentorial or infratentorial abnormalities (figure 1, A-B). There was no evidence of peripheral neuropathy on electroneuromyography. The CSF was acellular with normal glucose and protein levels and no oligoclonal bands. Extensive investigation for underlying infective, autoimmune, and metabolic etiologies was negative with the exception of high-titer anti-Purkinje cell autoantibodies detected by indirect immunohistochemistry4 in both the serum (titer 1/32,000) and the CSF (titer 1/1,000). All specific testing for known CNS autoantibodies were negative.4 Comprehensive tumor screening by total-body 18-fluoro-deoxyglucose PET (18FDG-PET), bone marrow biopsy, and dermatologic and gynecologic explorations revealed no occult malignancy. She received 6 cycles of high-dose IV methylprednisolone (1 g/d for 3 days), followed by 10 sessions of plasma exchange, without clinical improvement. She continued to have regular tumor screening with total-body 18FDG-PET.

Over the following 2 years, her neurologic status worsened, and she became unable to walk unassisted. CSF analysis and neuroimaging were unchanged. Three cycles of IV immunoglobulin (2 g/kg) were attempted, without clinical benefit. Thereafter, she stabilized but remained severely disabled. Anti-Purkinje cell autoantibodies were persistently positive in the serum and were later characterized as anti-ITPR1 antibodies.4

Following familial genetic counseling, she was tested positive for a detrimental germline mutation in the BRCA1 gene that was first identified in a relative affected with breast cancer (figure e-1 at Neurology.org/nn), and she thus entered a dedicated screening program for breast and ovarian cancers.

Six years later, a suspicious lymph node was detected on mammography. She underwent radical right mastectomy, revealing a bifocal ductal carcinoma (grade I; estrogen-receptor–positive (ER+) 100%, progesterone-receptor–positive (PR+) 90%, Her2/neu−), with 2 intrammary and 1 axillary metastatic lymph nodes. Immunopathology revealed substantial ITPR1 expression in both the breast tumor and the metastatic lymph nodes (figure 1, C-F). Local radiotherapy was considered unfeasible because of her comorbidities, and adjuvant tamoxifen was introduced. At 6-month follow-up, she was considered in tumor remission; her neurologic status was unchanged.

Discussion. Here, we report the case of a young woman presenting with autoimmune cerebellar ataxia and anti-ITPR1 antibodies, who 11 years after onset was diagnosed with breast cancer. Both the breast tumor and metastatic lymph nodes expressed ITPR1, suggesting that the long-standing cerebellar autoimmunity was in fact paraneoplastic.

So far, only 4 cases of cerebellar ataxia related to anti-ITPR1 autoimmunity have been published,4
and tumor association is limited to the present case. To date, it is thus impossible to draw any conclusion regarding the possible association of anti-ITPR1 antibodies to cancer. Still, ITPR1 is expressed in a number of tumors such as breast and liver cancers, melanomas, and lymphomas,5 and we thus expect anti-ITPR1 autoimmunity to potentially associate with these tumor types.

Our patient was diagnosed with breast cancer 11 years after the onset of the cerebellar syndrome, far longer than ever reported.6 Cancer was diagnosed while still subclinical, during scheduled assessments, within a BRCA1 tumor surveillance program that was established by oncologists. Our case underlines the importance for neurologists to carefully evaluate individual cancer risk in all patients with autoimmunity to intracellular antigens.


Study funding: No targeted funding.

Disclosures: G. Berzero reports no disclosures. Y. Haasen received research support from NIH, University of Oxford, and NHS Trust. L. Komorowski is employed by EUROIMMUN AG. M. Scharf holds a patent for a diagnostic test for the detection of autoantibodies against ITPR1 and is employed by EUROIMMUN Medizinische Labordiagnostika AG. C. Dehais, D. Leclercq, V. Fourchotte, B. Buecher, and J. Honnorat report no disclosures. F. Graus is on the editorial board of Lancet Neurology and receives licensing fees from EUROMMUN for the use of IgLON5 as a diagnostic test. J.-Y. Delattre is on the editorial board of The Oncologist and receives research support from Institut National du Cancer. D. Psimaras reports no disclosures. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Received November 8, 2016. Accepted in final form December 8, 2016.

Correspondence to Dr. Psimaras: dimitri.psimaras@aphp.fr


Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies
Giulia Berzero, Yael Hacohen, Lars Komorowski, et al.
Neurol Neuroimmunol Neuroinflamm 2017;4;
DOI 10.1212/NXI.0000000000000326

This information is current as of February 3, 2017

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/4/2/e326.full.html

Supplementary Material
Supplementary material can be found at:
http://nn.neurology.org/content/suppl/2017/02/03/4.2.e326.DC1

References
This article cites 6 articles, 1 of which you can access for free at:
http://nn.neurology.org/content/4/2/e326.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Gait disorders/ataxia
http://nn.neurology.org/cgi/collection/gait_disorders_ataxia
Paraneoplastic syndrome
http://nn.neurology.org/cgi/collection/paraneoplastic_syndrome

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.